Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.

Pajcini KV, Xu L, Shao L, Petrovic J, Palasiewicz K, Ohtani Y, Bailis W, Lee C, Wertheim GB, Mani R, Muthusamy N, Li Y, Meijerink JPP, Blacklow SC, Faryabi RB, Cherry S, Pear WS.

Sci Signal. 2017 Nov 14;10(505). pii: eaam6846. doi: 10.1126/scisignal.aam6846.

PMID:
29138297
2.

The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.

Girardi T, Vereecke S, Sulima SO, Khan Y, Fancello L, Briggs JW, Schwab C, de Beeck JO, Verbeeck J, Royaert J, Geerdens E, Vicente C, Bornschein S, Harrison CJ, Meijerink JP, Cools J, Dinman JD, Kampen KR, De Keersmaecker K.

Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.225. [Epub ahead of print]

3.

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.

Libouban MAA, de Roos JADM, Uitdehaag JCM, Willemsen-Seegers N, Mainardi S, Dylus J, de Man J, Tops B, Meijerink JPP, Storchová Z, Buijsman RC, Medema RH, Zaman GJR.

Oncotarget. 2017 Jun 13;8(24):38309-38325. doi: 10.18632/oncotarget.16213.

4.

Loss of CD44dim Expression from Early Progenitor Cells Marks T-Cell Lineage Commitment in the Human Thymus.

Canté-Barrett K, Mendes RD, Li Y, Vroegindeweij E, Pike-Overzet K, Wabeke T, Langerak AW, Pieters R, Staal FJ, Meijerink JP.

Front Immunol. 2017 Jan 20;8:32. doi: 10.3389/fimmu.2017.00032. eCollection 2017.

5.

IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.

Li Y, Buijs-Gladdines JG, Canté-Barrett K, Stubbs AP, Vroegindeweij EM, Smits WK, van Marion R, Dinjens WN, Horstmann M, Kuiper RP, Buijsman RC, Zaman GJ, van der Spek PJ, Pieters R, Meijerink JP.

PLoS Med. 2016 Dec 20;13(12):e1002200. doi: 10.1371/journal.pmed.1002200. eCollection 2016 Dec.

6.

Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.

Shen Y, Park CS, Suppipat K, Mistretta TA, Puppi M, Horton TM, Rabin K, Gray NS, Meijerink JPP, Lacorazza HD.

Leukemia. 2017 Jun;31(6):1314-1324. doi: 10.1038/leu.2016.339. Epub 2016 Nov 22.

PMID:
27872496
7.

The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.

Mendes RD, Canté-Barrett K, Pieters R, Meijerink JP.

Haematologica. 2016 Sep;101(9):1010-7. doi: 10.3324/haematol.2016.146381. Review.

8.

Lentiviral gene transfer into human and murine hematopoietic stem cells: size matters.

Canté-Barrett K, Mendes RD, Smits WK, van Helsdingen-van Wijk YM, Pieters R, Meijerink JP.

BMC Res Notes. 2016 Jun 16;9:312. doi: 10.1186/s13104-016-2118-z.

9.

Overexpression of LMO2 causes aberrant human T-Cell development in vivo by three potentially distinct cellular mechanisms.

Wiekmeijer AS, Pike-Overzet K, Brugman MH, van Eggermond MC, Cordes M, de Haas EF, Li Y, Oole E, van IJcken WF, Egeler RM, Meijerink JP, Staal FJ.

Exp Hematol. 2016 Sep;44(9):838-849.e9. doi: 10.1016/j.exphem.2016.06.002. Epub 2016 Jun 11.

PMID:
27302866
10.

HOXA-activated early T-cell progenitor acute lymphoblastic leukemia: predictor of poor outcome?

Meijerink JP, Canté-Barrett K, Vroegindeweij E, Pieters R.

Haematologica. 2016 Jun;101(6):654-6. doi: 10.3324/haematol.2016.145391. No abstract available.

11.

Trib2 Suppresses Tumor Initiation in Notch-Driven T-ALL.

Stein SJ, Mack EA, Rome KS, Pajcini KV, Ohtani T, Xu L, Li Y, Meijerink JP, Faryabi RB, Pear WS.

PLoS One. 2016 May 18;11(5):e0155408. doi: 10.1371/journal.pone.0155408. eCollection 2016.

12.

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.

Canté-Barrett K, Spijkers-Hagelstein JA, Buijs-Gladdines JG, Uitdehaag JC, Smits WK, van der Zwet J, Buijsman RC, Zaman GJ, Pieters R, Meijerink JP.

Leukemia. 2016 Sep;30(9):1832-43. doi: 10.1038/leu.2016.83. Epub 2016 Apr 22.

13.

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia.

Watanabe-Smith K, Tognon C, Tyner JW, Meijerink JP, Druker BJ, Agarwal A.

Leukemia. 2016 Sep;30(9):1950-3. doi: 10.1038/leu.2016.95. Epub 2016 Apr 27. No abstract available.

14.

Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains.

Canté-Barrett K, Uitdehaag JC, Meijerink JP.

Haematologica. 2016 May;101(5):e189-91. doi: 10.3324/haematol.2015.138248. Epub 2016 Jan 27. No abstract available.

15.

ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling.

Goossens S, Radaelli E, Blanchet O, Durinck K, Van der Meulen J, Peirs S, Taghon T, Tremblay CS, Costa M, Farhang Ghahremani M, De Medts J, Bartunkova S, Haigh K, Schwab C, Farla N, Pieters T, Matthijssens F, Van Roy N, Best JA, Deswarte K, Bogaert P, Carmichael C, Rickard A, Suryani S, Bracken LS, Alserihi R, Canté-Barrett K, Haenebalcke L, Clappier E, Rondou P, Slowicka K, Huylebroeck D, Goldrath AW, Janzen V, McCormack MP, Lock RB, Curtis DJ, Harrison C, Berx G, Speleman F, Meijerink JP, Soulier J, Van Vlierberghe P, Haigh JJ.

Nat Commun. 2015 Jan 7;6:5794. doi: 10.1038/ncomms6794.

16.

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.

Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P.

Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9.

17.

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.

Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, Jacobs K, Geerdens E, Gianfelici V, Hulselmans G, Fiers M, Aerts S, Meijerink JP, Tousseyn T, Cools J.

Blood. 2014 Nov 13;124(20):3092-100. doi: 10.1182/blood-2014-04-566687. Epub 2014 Sep 5.

18.

Angiopoietin-like protein 3 promotes preservation of stemness during ex vivo expansion of murine hematopoietic stem cells.

Farahbakhshian E, Verstegen MM, Visser TP, Kheradmandkia S, Geerts D, Arshad S, Riaz N, Grosveld F, van Til NP, Meijerink JP.

PLoS One. 2014 Aug 29;9(8):e105642. doi: 10.1371/journal.pone.0105642. eCollection 2014.

19.

CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.

Sarmento LM, Póvoa V, Nascimento R, Real G, Antunes I, Martins LR, Moita C, Alves PM, Abecasis M, Moita LF, Parkhouse RM, Meijerink JP, Barata JT.

Oncogene. 2015 Jun 4;34(23):2978-90. doi: 10.1038/onc.2014.248. Epub 2014 Aug 18.

PMID:
25132270
20.

PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events.

Mendes RD, Sarmento LM, Canté-Barrett K, Zuurbier L, Buijs-Gladdines JG, Póvoa V, Smits WK, Abecasis M, Yunes JA, Sonneveld E, Horstmann MA, Pieters R, Barata JT, Meijerink JP.

Blood. 2014 Jul 24;124(4):567-78. doi: 10.1182/blood-2014-03-562751. Epub 2014 Jun 5.

21.

Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.

Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC, Sanchez-Martin M, Perez-Garcia A, Rigo I, Castillo M, Indraccolo S, Cross JR, de Stanchina E, Paietta E, Racevskis J, Rowe JM, Tallman MS, Basso G, Meijerink JP, Cordon-Cardo C, Califano A, Ferrando AA.

Cancer Cell. 2013 Dec 9;24(6):766-76. doi: 10.1016/j.ccr.2013.10.022. Epub 2013 Nov 27.

22.

Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors.

Zuurbier L, Gutierrez A, Mullighan CG, Canté-Barrett K, Gevaert AO, de Rooi J, Li Y, Smits WK, Buijs-Gladdines JG, Sonneveld E, Look AT, Horstmann M, Pieters R, Meijerink JP.

Haematologica. 2014 Jan;99(1):94-102. doi: 10.3324/haematol.2013.090233. Epub 2013 Aug 23.

23.

Breakpoint sites disclose the role of the V(D)J recombination machinery in the formation of T-cell receptor (TCR) and non-TCR associated aberrations in T-cell acute lymphoblastic leukemia.

Larmonie NS, Dik WA, Meijerink JP, Homminga I, van Dongen JJ, Langerak AW.

Haematologica. 2013 Aug;98(8):1173-84. doi: 10.3324/haematol.2012.082156. Review.

24.

Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines.

Duijkers FA, de Menezes RX, Goossens-Beumer IJ, Stumpel DJ, Admiraal P, Pieters R, Meijerink JP, van Noesel MM.

Cell Oncol (Dordr). 2013 Oct;36(5):351-62. doi: 10.1007/s13402-013-0140-x. Epub 2013 Jul 18.

PMID:
23864224
25.

Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration.

Duijkers FA, Meijerink JP, Pieters R, van Noesel MM.

Gene. 2013 May 25;521(1):62-8. doi: 10.1016/j.gene.2013.03.029. Epub 2013 Mar 21.

PMID:
23523856
26.

Myocyte enhancer factor 2C in hematopoiesis and leukemia.

Canté-Barrett K, Pieters R, Meijerink JP.

Oncogene. 2014 Jan 23;33(4):403-10. doi: 10.1038/onc.2013.56. Epub 2013 Feb 25. Review.

PMID:
23435431
27.

Inactivation of the Cdkn2a locus cooperates with HMGA1 to drive T-cell leukemogenesis.

Di Cello F, Dhara S, Hristov AC, Kowalski J, Elbahloul O, Hillion J, Roy S, Meijerink JP, Winter SS, Larson RS, Huso DL, Resar L.

Leuk Lymphoma. 2013 Aug;54(8):1762-8. doi: 10.3109/10428194.2013.764422. Epub 2013 Feb 1.

PMID:
23311322
28.

The nuclear effector of Wnt-signaling, Tcf1, functions as a T-cell-specific tumor suppressor for development of lymphomas.

Tiemessen MM, Baert MR, Schonewille T, Brugman MH, Famili F, Salvatori DC, Meijerink JP, Ozbek U, Clevers H, van Dongen JJ, Staal FJ.

PLoS Biol. 2012;10(11):e1001430. doi: 10.1371/journal.pbio.1001430. Epub 2012 Nov 20.

29.

A novel and fast normalization method for high-density arrays.

van Iterson M, Duijkers FA, Meijerink JP, Admiraal P, van Ommen GJ, Boer JM, van Noesel MM, Menezes RX.

Stat Appl Genet Mol Biol. 2012 Jul 12;11(4). pii: /j/sagmb.2012.11.issue-4/1544-6115.1753/1544-6115.1753.xml. doi: 10.1515/1544-6115.1753.

PMID:
22850064
30.

High frequency of copy number alterations in myeloid leukaemia of Down syndrome.

Blink M, van den Heuvel-Eibrink MM, Aalbers AM, Balgobind BV, Hollink IH, Meijerink JP, van der Velden VH, Beverloo BH, de Haas V, Hasle H, Reinhardt D, Klusmann JH, Pieters R, Calado RT, Zwaan CM.

Br J Haematol. 2012 Sep;158(6):800-3. doi: 10.1111/j.1365-2141.2012.09224.x. Epub 2012 Jul 7. No abstract available.

PMID:
22775985
31.

The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.

Zuurbier L, Petricoin EF 3rd, Vuerhard MJ, Calvert V, Kooi C, Buijs-Gladdines JG, Smits WK, Sonneveld E, Veerman AJ, Kamps WA, Horstmann M, Pieters R, Meijerink JP.

Haematologica. 2012 Sep;97(9):1405-13. doi: 10.3324/haematol.2011.059030. Epub 2012 Apr 4.

32.

Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.

Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JP, Beverloo HB, Zimmermann M, de Haas V, Richards SM, Vora AJ, Mitchell CD, Russell LJ, Schwab C, Harrison CJ, Moorman AV, van den Heuvel-Eibrink MM, den Boer ML, Zwaan CM.

Leukemia. 2012 Oct;26(10):2204-11. doi: 10.1038/leu.2012.84. Epub 2012 Mar 22.

PMID:
22441210
33.

Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.

Della Gatta G, Palomero T, Perez-Garcia A, Ambesi-Impiombato A, Bansal M, Carpenter ZW, De Keersmaecker K, Sole X, Xu L, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Meijerink JP, Califano A, Ferrando AA.

Nat Med. 2012 Feb 26;18(3):436-40. doi: 10.1038/nm.2610.

34.

High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.

Duijkers FA, Gaal J, Meijerink JP, Admiraal P, Pieters R, de Krijger RR, van Noesel MM.

Am J Pathol. 2012 Mar;180(3):1223-31. doi: 10.1016/j.ajpath.2011.12.003. Epub 2011 Dec 25.

PMID:
22203052
35.

NKL homeobox genes in leukemia.

Homminga I, Pieters R, Meijerink JP.

Leukemia. 2012 Apr;26(4):572-81. doi: 10.1038/leu.2011.330. Epub 2011 Nov 18. Review.

PMID:
22094586
36.

Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements.

Homminga I, Vuerhard MJ, Langerak AW, Buijs-Gladdines J, Pieters R, Meijerink JP.

Haematologica. 2012 Feb;97(2):258-61. doi: 10.3324/haematol.2011.051722. Epub 2011 Nov 4.

37.

Correct interpretation of T-ALL oncogene expression relies on normal human thymocyte subsets as reference material.

Larmonie NS, Dik WA, van der Velden VH, Hoogeveen PG, Beverloo HB, Meijerink JP, van Dongen JJ, Langerak AW.

Br J Haematol. 2012 Apr;157(1):142-6. doi: 10.1111/j.1365-2141.2011.08926.x. Epub 2011 Nov 5. No abstract available.

PMID:
22053714
38.

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.

Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M, Tritapoe J, Hixon JA, Silveira AB, Cardoso BA, Sarmento LM, Correia N, Toribio ML, Kobarg J, Horstmann M, Pieters R, Brandalise SR, Ferrando AA, Meijerink JP, Durum SK, Yunes JA, Barata JT.

Nat Genet. 2011 Sep 4;43(10):932-9. doi: 10.1038/ng.924.

PMID:
21892159
39.

In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.

Homminga I, Zwaan CM, Manz CY, Parker C, Bantia S, Smits WK, Higginbotham F, Pieters R, Meijerink JP.

Blood. 2011 Aug 25;118(8):2184-90. doi: 10.1182/blood-2011-02-337840. Epub 2011 Jul 5.

40.

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels.

Duijkers FA, Gaal J, Meijerink JP, Admiraal P, Pieters R, de Krijger RR, van Noesel MM.

Cell Oncol (Dordr). 2011 Oct;34(5):409-17. doi: 10.1007/s13402-011-0048-2. Epub 2011 May 31.

41.

PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.

Kleppe M, Soulier J, Asnafi V, Mentens N, Hornakova T, Knoops L, Constantinescu S, Sigaux F, Meijerink JP, Vandenberghe P, Tartaglia M, Foa R, Macintyre E, Haferlach T, Cools J.

Blood. 2011 Jun 30;117(26):7090-8. doi: 10.1182/blood-2010-10-314286. Epub 2011 May 6.

42.

Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.

Homminga I, Pieters R, Langerak AW, de Rooi JJ, Stubbs A, Verstegen M, Vuerhard M, Buijs-Gladdines J, Kooi C, Klous P, van Vlierberghe P, Ferrando AA, Cayuela JM, Verhaaf B, Beverloo HB, Horstmann M, de Haas V, Wiekmeijer AS, Pike-Overzet K, Staal FJ, de Laat W, Soulier J, Sigaux F, Meijerink JP.

Cancer Cell. 2011 Apr 12;19(4):484-97. doi: 10.1016/j.ccr.2011.02.008.

43.

Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition.

Szczepanski T, van der Velden VH, Waanders E, Kuiper RP, Van Vlierberghe P, Gruhn B, Eckert C, Panzer-Grümayer R, Basso G, Cavé H, Stadt UZ, Campana D, Schrauder A, Sutton R, van Wering E, Meijerink JP, van Dongen JJ.

J Clin Oncol. 2011 Apr 20;29(12):1643-9. doi: 10.1200/JCO.2010.30.2877. Epub 2011 Feb 28.

PMID:
21357790
44.

Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia.

Meijerink JP.

Best Pract Res Clin Haematol. 2010 Sep;23(3):307-18. doi: 10.1016/j.beha.2010.08.002. Epub 2010 Oct 30. Review.

PMID:
21112032
45.

The TLX1 oncogene drives aneuploidy in T cell transformation.

De Keersmaecker K, Real PJ, Gatta GD, Palomero T, Sulis ML, Tosello V, Van Vlierberghe P, Barnes K, Castillo M, Sole X, Hadler M, Lenz J, Aplan PD, Kelliher M, Kee BL, Pandolfi PP, Kappes D, Gounari F, Petrie H, Van der Meulen J, Speleman F, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Soulier J, Avran D, Cavé H, Dastugue N, Raimondi S, Meijerink JP, Cordon-Cardo C, Califano A, Ferrando AA.

Nat Med. 2010 Nov;16(11):1321-7. doi: 10.1038/nm.2246. Epub 2010 Oct 24.

46.

NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.

Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JG, Kooi C, Smits WK, Sonneveld E, Veerman AJ, Kamps WA, Horstmann M, Petricoin EF 3rd, Pieters R, Meijerink JP.

Leukemia. 2010 Dec;24(12):2014-22. doi: 10.1038/leu.2010.204. Epub 2010 Sep 23.

PMID:
20861909
47.

Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.

Schotte D, Lange-Turenhout EA, Stumpel DJ, Stam RW, Buijs-Gladdines JG, Meijerink JP, Pieters R, Den Boer ML.

Haematologica. 2010 Oct;95(10):1675-82. doi: 10.3324/haematol.2010.023481. Epub 2010 May 21.

48.

Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.

Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, Graux C, Van Roosbroeck K, Ferrando AA, Langerak AW, Meijerink JP, Sigaux F, Haferlach T, Wlodarska I, Vandenberghe P, Soulier J, Cools J.

Nat Genet. 2010 Jun;42(6):530-5. doi: 10.1038/ng.587. Epub 2010 May 16.

49.

High-resolution identification of balanced and complex chromosomal rearrangements by 4C technology.

Simonis M, Klous P, Homminga I, Galjaard RJ, Rijkers EJ, Grosveld F, Meijerink JP, de Laat W.

Nat Methods. 2009 Nov;6(11):837-42. doi: 10.1038/nmeth.1391. Epub 2009 Oct 11.

PMID:
19820713
50.

WT1 mutations in T-ALL.

Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, Allen CG, Gale RE, Linch DC, Palomero T, Real P, Murty V, Yao X, Richards SM, Goldstone A, Rowe J, Basso G, Wiernik PH, Paietta E, Pieters R, Horstmann M, Meijerink JP, Ferrando AA.

Blood. 2009 Jul 30;114(5):1038-45. doi: 10.1182/blood-2008-12-192039. Epub 2009 Jun 3.

Supplemental Content

Loading ...
Support Center